Table II.

Complications and treatments of COVID-19 patients with and without CRS before and after propensity score matching

Complications and treatments	Unmatched				Matched (1:1)†
	Without CRS N = 1100	With CRS N = 72	P value	Adjusted P value∗	Without CRS N = 72	With CRS N = 72	P value
Complications, N (%)
Acute liver injury	74 (6.7)	5 (6.9)	.81	.43	6 (8.3)	5 (6.9)	.75
ARDS	66 (6.0)	4 (5.6)	.88	.79	4 (5.6)	4 (5.6)	.99
Acute kidney injury	61 (5.5)	2 (2.8)	.42	.24	4 (5.6)	2 (2.8)	.40
Acute myocardial injury	29 (2.6)	2 (2.8)	.72	.88	1 (1.4)	2 (2.8)	.56
Shock	7 (0.6)	2 (2.8)	.10	.17	0 (0)	2 (2.8)	.15
In-hospital treatments, N (%)
Antiviral treatment	1027 (93.4)	65 (90.3)	.31	.30	68 (94.4)	65 (90.3)	.35
Antibiotic treatment	799 (72.6)	51 (70.8)	.73	.55	49 (68.1)	51 (70.8)	.72
Oxygen supplementation	871 (79.2)	58 (80.6)	.78	.79	57 (79.2)	58 (80.6)	.84
Mechanical ventilation	43 (3.9)	2 (2.8)	.62	.61	2 (2.8)	2 (2.8)	.99
Glucocorticoid therapy	281 (25.5)	14 (19.4)	.25	.15	16 (22.2)	14 (19.4)	.68
Intravenous immunoglobulin therapy	177 (16.1)	12 (16.7)	.90	.94	14 (19.4)	12 (16.7)	.66

ARDS, Acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; CRS, chronic rhinosinusitis.

Data are presented as numbers with percentage for categorical variables.

The χ² or Fisher's exact test was applied to compare the difference in proportions between groups.

^∗In adjusted logistic regression analysis, adjusted variables included age, gender, smoking, and comorbidities (hypertension, diabetes, cardiovascular disease, cerebrovascular diseases, malignancy, chronic liver diseases, chronic kidney diseases, allergic rhinitis, asthma, and chronic obstructive pulmonary disease).

^†Age, gender, smoking status, and comorbidities were selected for propensity score matching. Please see Table I.